« Return to News | R&D Trends

Oncodesign, KU Leuven, Ipsen collaborate on advancing drug discovery in Parkinson's disease

Wednesday, December 19, 2012 11:11 AM

Oncodesign, a biotech based in France, and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the Katholieke Universiteit Leuven, have entered into a research collaboration to evaluate, along with a global specialty-driven pharmaceutical company Ipsen, Oncodesign’s compounds in multiple pharmacology models for Parkinson's disease.

The collaboration builds on Oncodesign's LRRK2 program with advanced Nanocyclix lead molecules that was partnered with Ipsen in January 2012.
 
“Our partnership with Ipsen on the discovery of novel therapeutic agents in Parkinson’s disease has advanced to a stage where we can use further in-depth expertise and advanced pharmacology models to position our leads,” said Jan Hoflack, Ph.D., chief scientific officer and head of Oncodesign's discovery activities.  “We are very excited to collaborate with KU Leuven to advance our understanding of both our inhibitors and the LRRK2 target.”

Oncodesign and LNGT will closely collaborate to advance Oncodesign's Parkinson’s disease program towards clinical development. LNGT will receive full financial support from Oncodesign for these activities.  
 
“This collaboration with Oncodesign is a perfect example of translational research in action,” said Veerle Baekelandt, Ph.D., principle investigator of LNGT. “Parkinson’s disease has been the focus of our research for more than 10 years now. We are very pleased that Oncodesign has selected our lab as a partner for advancing their kinase program.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.